Bayer's Farm-First Pivot Meets a Pharma Cash-Out as Two Engines Pull the Same Stock
Published on 09/22/2026 at 07:30 | Editorial boerse-global.de
Bayer's crop science division is no longer waiting in the wings of the restructuring debate. Concrete commercialization steps have moved to center stage, and the market has begun to reward them. On Monday the stock advanced 2.1% to close at EUR 49.04 on Xetra — a move that coincided with news that the Grünenthal GmbH had agreed to acquire the oncology drug Stivarga, in a transaction worth up to EUR 375 million to the Leverkusen-based group.
The two developments capture the twin tracks Bayer is now running. On one side, the company is shedding mature assets to free up liquidity and cut day-to-day operational complexity, sharpening its focus on more promising therapeutic areas. On the other, it is pushing new agricultural technology into the field at scale.
A Biofuel Channel Opens in the American South
Central to the agricultural push is a commercial agreement with Finland's Neste aimed at scaling the cultivation of newgold winter rapeseed across the southern Great Plains of the United States for biofuel production. The arrangement gives Bayer an additional outlet in renewable energy, a channel that sits outside its traditional crop-protection revenue base.
Alongside the Neste tie-up, Bayer is driving global distribution of newly developed crop protection and seed technologies. The insecticide Plenexos and the corn system Preceon are already in active commercialization. How quickly farmers adopt these systems — and whether agricultural commodity prices hold up — will shape the revenue they generate. A further pillar rests on Vyconic 1 for soybeans, whose launch in the US and Canada is expected in 2027; any delay there would weaken a key plank of the medium-term growth plan.
Should investors sell immediately? Or is it worth buying Bayer?
The Regulatory Wins Stacking Up in Pharma
The pharmaceutical pipeline has delivered its own run of good news. On September 9, the US Food and Drug Administration granted accelerated approval to the targeted therapy Sevabertinib as a first-line treatment for adults with HER2-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer. The FDA followed last Friday by approving Finerenone — marketed as Kerendia — for a new indication covering chronic kidney disease in patients with type 1 diabetes. Such label extensions shore up the market position of established active ingredients and broaden the future base in chronic indications.
Missouri Remains the Swing Factor
Running against these operational strides is the long-simmering US litigation. Roughly a week ago, Bayer subsidiary Monsanto asked a court in Missouri to approve a settlement proposal worth USD 7.25 billion. According to Reuters, the deal is designed to resolve around 65,000 lawsuits alleging cancer risks linked to the herbicide Roundup. Whether the proposal ultimately delivers legal closure depends on judicial confirmation, and every procedural turn is being watched closely by the market.
That legal overhang explains why the stock's fate stays tethered to courtroom outcomes even as the product story improves. New products must generate substantial earnings contributions before the group gains the room to offset potential burdens from past acquisitions on a lasting basis.
What the Bulls and Bears Are Watching
In the optimistic case, Bayer commercializes its blockbuster candidates faster than expected. Preceon and Plenexos address core challenges in global agriculture, and the Neste cooperation would sustainably strengthen the US biofuel business. A 32% gain since the start of the year gives the shares a solid cushion that could, if the successes materialize, open the path to new highs.
The risk scenario is dominated by legal uncertainty and operational hurdles. Should the Missouri settlement hearing fail to bring meaningful relief, fresh setbacks from further litigation loom, with arbitration rulings or drawn-out US appeals consuming significant management capacity and financial resources. Beyond the courtroom, a hesitant farmer uptake or a slump in agricultural commodity prices could weigh on sales of Plenexos and Preceon.
For investors, the profile is clear enough. As long as crop science execution stays on schedule and the rollouts of Plenexos and Preceon underpin the earnings base, the upward trend holds. If risk perception shifts on new glyphosate burdens, a marked correction becomes the threat. The next directional milestones are the deepening market penetration of the new agricultural products in North America and preparations for the Vyconic 1 launch slated for 2027 in the US and Canada — the yardsticks by which Bayer's strategic turn will ultimately be judged.
Ad
Bayer Stock: New Analysis - 22 September
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
